SavedAdd your journal

Journals / Çocuk Dergisi / 2006 / Cilt: 6 - Sayı: 4

Renal osteodystrophy in children

Çocuklarda renal östeodistrofi

Harika ALPAY
Nihal ÖZDEMİR
Pages
238–243
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, an approach to the management and treatment of ROD in children with chronic renal failure is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Childhood renal osteodystrophy (ROD) is the consequence of disturbances in calcium and phosphorus metabolism and their complex interrelationship with parathyroid hormone and vitamin D.
📊
Key Findings & Data:Unlike adults, ROD in children may lead to growth failure and permanent bone deformities which may cause disabling complications.
💡
Conclusion & Impact:In this review, an approach to the management and treatment of ROD in children with chronic renal failure is presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Böbrek yetmezliği · Diyet tedavisi · Renal osteodistrofi

Abstract

Childhood renal osteodystrophy (ROD) is the consequence of disturbances in calcium and phosphorus metabolism and their complex interrelationship with parathyroid hormone and vitamin D. Unlike adults, ROD in children may lead to growth failure and permanent bone deformities which may cause disabling complications. In this review, an approach to the management and treatment of ROD in children with chronic renal failure is presented.

Özet

Çocuklarda renal osteodistrofi (ROD), kalsiyum, fosfor metabolizmasında değişiklikler ile paratiroid hormonu ve D vitamini arasındaki karmaşık ilişki sonucu gelişen bir komplikasyondur. Erişkinlerden farklı olarak, böbrek yetersizliği olan çocuklarda görülen ROD, büyüme geriliği ve kalıcı kemik deformiteleri ile birlikte ileride fiziksel özürlere neden olabilir. Bu derlemede, böbrek yetersizliği olan çocuklarda ROD’de yaklaşım ve tedavi sunulmuştur.

🔖

Cite This Article

ALPAY, H., ÖZDEMİR, N. (2006). Renal osteodystrophy in children. Çocuk Dergisi, Cilt: 6 - Sayı: 4, 238–243. https://ajindex.com/articles/160838

References (18)

  1. Hruska K. Pathophysiology of renal osteodystrophy. Pediatr Nephrol 2000; 14:636-40
  2. Avner ED, Harmon WE, Niaudet P. Pediatric Nephrology. 5th ed. USA: Lippincott, 2004
  3. Neu AM, Ho PL, McDonald RA, et al. Chronic dialysis in children and adolescents. The 2001 NAPRTCS annual report. Pediatr Nephrol 2002; 17:656-63
  4. Millinler DS, Zinsmeister AR, Lieberman E, et al. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38:931-6
  5. Norman LJ, Coleman JE, Macdonald I, Tomsett A, Watson AR. Nutrition and growth in relation to severity of renal disease in children. Pediatr Nephrol 2000; 14:833-6
  6. Salusky IB, Ramirez JA, Oppenheim W, et all Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45:253-8
  7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:1-201
  8. Salusky IB, Jüppner H. New PTH assays and renal osteodystrophy. Pediatr NephroJ 2004; 19:709-13
  9. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002: 21-4
  10. Barrett IR, Papadimitriou DG. Skeletal disorders in children with renal failure. J Pediatr Orthop 1996; 16:264-72
  11. Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21:151-9
  12. Bakr AM. Bone mineral density and bone turnover markers in children with chronic renal failure. Pediatr Nephrol 2004; 19:1390-3
  13. Tasic V. Management of renal osteodystrophy in children. Turk J Pediatr 2005: 13-8
  14. Schaefer K, Sheer J, Asmus G, et al. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6:171-5
  15. Sanchez CP. Chronotherapy of high-dose active vitamin D3: is evening dosing preferable? Pediatr Nephrol 2004; 19:722-3
  16. Goodman WG, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-83
  17. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55:299-307
  18. Pieper AK, Haffner D, Hoppe B, et al. A randomized crossover trial comparing sevelamer with ca